Informações:
Falhas:
ID
33905
Descrição
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01925274
Link
https://clinicaltrials.gov/show/NCT01925274
Palavras-chave
Versões (1)
- 06/01/2019 06/01/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
6 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Metastatic Colorectal Cancer NCT01925274
Eligibility Metastatic Colorectal Cancer NCT01925274
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Colorectal Cancer NCT01925274
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Secondary malignant neoplasm of large intestine KRAS Wild Type | Secondary malignant neoplasm of large intestine NRAS Wild Type
Item
kras and nras wild type metastatic colorectal cancer
boolean
C0346973 (UMLS CUI [1,1])
C1537502 (UMLS CUI [1,2])
C1883559 (UMLS CUI [1,3])
C0346973 (UMLS CUI [2,1])
C0809246 (UMLS CUI [2,2])
C1883559 (UMLS CUI [2,3])
C1537502 (UMLS CUI [1,2])
C1883559 (UMLS CUI [1,3])
C0346973 (UMLS CUI [2,1])
C0809246 (UMLS CUI [2,2])
C1883559 (UMLS CUI [2,3])
Disease Progression | Status post Treatment Secondary malignant neoplasm of large intestine | irinotecan | oxaliplatin | fluoropyrimidine
Item
progression following treatment for colorectal cancer with irinotecan, oxaliplatin and fluoropyrimidine therapy in the metastatic setting.
boolean
C0242656 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0346973 (UMLS CUI [2,3])
C0123931 (UMLS CUI [3])
C0069717 (UMLS CUI [4])
C0596581 (UMLS CUI [5])
C0231290 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0346973 (UMLS CUI [2,3])
C0123931 (UMLS CUI [3])
C0069717 (UMLS CUI [4])
C0596581 (UMLS CUI [5])
ECOG performance status
Item
eastern cooperative oncology group [ecog] performance status of 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
Measurable lesion Quantity
Item
at least one measurable lesion by response evaluation criterion in solid tumors [recist]
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Cytotoxic Chemotherapy Quantity Secondary malignant neoplasm of large intestine
Item
more than 2 prior cytotoxic chemotherapy regimens for metastatic colorectal cancer.
boolean
C0677881 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0346973 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0346973 (UMLS CUI [1,3])
PI3K Inhibitor | mTOR Inhibitor | AKT1 gene Inhibitor | AKT2 gene Inhibitor | AKT3 gene Inhibitor | EGFR inhibitor
Item
prior treatment with a pi3k, mtor, akt or egfr inhibitor
boolean
C1519050 (UMLS CUI [1])
C2746052 (UMLS CUI [2])
C0812228 (UMLS CUI [3,1])
C1999216 (UMLS CUI [3,2])
C0812230 (UMLS CUI [4,1])
C1999216 (UMLS CUI [4,2])
C1332074 (UMLS CUI [5,1])
C1999216 (UMLS CUI [5,2])
C1443775 (UMLS CUI [6])
C2746052 (UMLS CUI [2])
C0812228 (UMLS CUI [3,1])
C1999216 (UMLS CUI [3,2])
C0812230 (UMLS CUI [4,1])
C1999216 (UMLS CUI [4,2])
C1332074 (UMLS CUI [5,1])
C1999216 (UMLS CUI [5,2])
C1443775 (UMLS CUI [6])
Irinotecan Discontinued | Etiology Toxicity
Item
patients who have discontinued treatment with prior irinotecan therapy due to toxicity.
boolean
C0123931 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0015127 (UMLS CUI [2,1])
C0600688 (UMLS CUI [2,2])
C1444662 (UMLS CUI [1,2])
C0015127 (UMLS CUI [2,1])
C0600688 (UMLS CUI [2,2])
Radiotherapy to pelvis | Radiotherapy to abdomen
Item
prior radiation to the pelvis or abdomen
boolean
C1536155 (UMLS CUI [1])
C1997554 (UMLS CUI [2])
C1997554 (UMLS CUI [2])
Lung Diseases, Interstitial
Item
patients with history of interstitial lung disease.
boolean
C0206062 (UMLS CUI [1])